Home › Kanser sa Esophagus › Pennsylvania › Pittsburgh
Pag-aaral pangklinika para sa Kanser sa Esophagus sa Pittsburgh, PA
Isang pag-aaral para sa Kanser sa Esophagus ang naghahanap ng mga kalahok sa isang site sa loob o malapit sa Pittsburgh. Buksan ito upang makita kung sino ang makakasali at kung paano makipag-ugnayan sa koponan ng pag-aaral.
Opisyal na teksto ng pag-aaral (English)
A Study to Evaluate Investigational Agents With or Without Pembrolizumab (MK-3475) in Participants With Advanced Esophageal Cancer Previously Exposed to Programmed Cell Death 1 Protein (PD-1)/ Programmed Cell Death Ligand 1 (PD-L1) Treatment (MK-3475-06B)
Nagre-recruitPhase 1/2
- UPMC Hillman Cancer Center-UPMC ( Site 4904), Pittsburgh
Distance-Based Exercise to Preserve Function and Prevent Disability
Nagre-recruit
- UPMC Hillman Cancer Center, Pittsburgh
A Study of LY4257496 in Participants With Cancer (OMNIRAY)
Nagre-recruitPhase 1
- University of Pittsburgh Medical Center, Pittsburgh
Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
Nagre-recruitPhase 1/2
- Allegheny Health Network, Pittsburgh
SKL35501 With SKL35502 Imaging in Adults With NTSR1 Positive Advanced Solid Tumors
Nagre-recruitPhase 1
- UPMC Hillman Cancer Center, Pittsburgh
Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2
Nagre-recruitPhase 3
- Research Site, Pittsburgh
- Research Site, Pittsburgh
Substudy 06D: Combination Therapies in Second Line (2L) Gastroesophageal Adenocarcinoma (MK-3475-06D/Keymaker-U06)
Nagre-recruitPhase 1/2
- UPMC Hillman Cancer Center-UPMC ( Site 8904), Pittsburgh
Substudy 06C: A Study of Investigational Agents With Pembrolizumab (MK-3475) and Chemotherapy in Participants With First-Line Locally Advanced Unresectable/Metastatic Gastroesophageal Adenocarcinoma (MK-3475-06C/KEYMAKER-U06)
Nagre-recruitPhase 1/2
- UPMC Hillman Cancer Center-UPMC ( Site 6904), Pittsburgh
Lead-212 PSV359 Therapy for Patients With Solid Tumors
Nagre-recruitPhase 1/2
- University of Pittsburgh Medical Center, Pittsburgh
Impact of Prehabilitation in Oncology Via Exercise- Esophageal (IMPROVE-Esophageal)
Nagre-recruit
- UPMC Hillman Cancer Center, Pittsburgh
Patient Preference for Subcutaneous vs. Intravenous Immune Therapy
Nagre-recruitPhase 2
- UPMC Hillman Cancer Center, Pittsburgh
Esophageal Cancer Risk Registry
Nagre-recruitObservasyonal na pag-aaral
- Department of Cardiothoracic Surgery, Pittsburgh
Outcomes After Esophagectomy With a Focus on Minimally Invasive Esophagectomy and Quality of Life
Nagre-recruitObservasyonal na pag-aaral
- University of Pittsburgh Medical Center - Department of Cardiothoracic Surgery, Pittsburgh
- UPMC - Hillman Cancer Center, Pittsburgh
The MOMENTUM Study: The Multiple Outcome Evaluation of Radiation Therapy Using the MR-Linac Study
Nagre-recruitObservasyonal na pag-aaral
- Allegheny Health Network, Pittsburgh
Intra-tumoral (IT) Injection of vvDD-hIL2-2-RG-1 for Metastatic Gastrointestinal and Peritoneal Tumors
Nagre-recruitPhase 1
- AHN West Penn Hospital, Pittsburgh
Pag-aaral para sa Kanser sa Esophagus sa ibang lungsod
- Houston, TX36 pag-aaral
- Boston, MA23 pag-aaral
- New York City, NY22 pag-aaral
- Nashville, TN19 pag-aaral
- St. Louis, MO17 pag-aaral
- Los Angeles, CA15 pag-aaral
- Baldwin Park, CA14 pag-aaral
- Grand Rapids, MI14 pag-aaral
- Philadelphia, PA13 pag-aaral
- San Antonio, TX12 pag-aaral
- Dallas, TX11 pag-aaral
- Rochester, MN11 pag-aaral
Iba pang pag-aaral sa Pittsburgh
- Non-Small Cell Lung Cancer48 pag-aaral
- Kanser (lahat ng uri)41 pag-aaral
- Kanser sa Suso39 pag-aaral
- Colorectal Cancer32 pag-aaral
- Metastatic Cancer31 pag-aaral
- Melanoma31 pag-aaral
- Kanser sa Ovary30 pag-aaral
- Kanser ng Endometrium23 pag-aaral
- Kanser sa Prostate23 pag-aaral
- Kanser sa Baga23 pag-aaral
- Squamous Cell Carcinoma ng Ulo at Leeg22 pag-aaral
- Stroke22 pag-aaral
Mula sa ClinicalTrials.gov, na-kuha noong Okt 6, 2026. Ang bawat pag-aaral ay may sariling pamantayan sa eligibility; ang koponan ng pag-aaral ang magdedesisyon kung sino ang makakasali.